|
|||||
|
|
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial |
|
| Authors: | Charlotte C. van Ruiten MD Dick J. Veltman MD PhD Madelief Wijdeveld MSc Jennifer S ten Kulve MD PhD Mark H. H. Kramer MD PhD Max Nieuwdorp MD PhD Richard G. IJzerman MD PhD |
| Affiliation: | 1. Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, The Netherlands;2. Department of Psychiatry, Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, The Netherlands;3. Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, The Netherlands Department of Vascular Medicine, Amsterdam University Medical Center, Location AMC, Amsterdam, The Netherlands |
| Abstract: | |
| Keywords: | central regulation of appetite dapagliflozin exenatide functional neuroimaging GLP-1 receptor agonist obesity SGLT2 inhibitor type 2 diabetes |